Disecting This mREIT: Crexus Investment Corp (CXS)

Page 1 of 2

Since 2008, Crexus Investment Corp (NYSE:CXS) has operated as a mortgage REIT with investments in commercial mortgage loans, commercial mortgage backed securities, commercial real property, Agency Residential mortgage backed securities, commercial real estate debt and other commercial real estate related assets. Since the company is operating as a mortgage REIT, its objective is to provide its shareholders with high risk-adjusted returns, primarily through dividends.

Crexus Investment Corp (NYSE:CXS)Investment Portfolio

For the purpose of reporting, the company has divided its investment portfolio into two segments; commercial real estate debt & preferred equity and real estate properties. The following graphs show the percentage of each type of security within the commercial real estate debt & preferred equity segment and the company’s investment portfolio in general.

It is evident from the above graph that around 87% of the company’s investment portfolio was commercial real estate loans, while 8% was real estate investments. Within the commercial real estate debt & preferred equity, a large concentration (71%) are fixed rate, while the rest are adjustable-rate securities.

Recent Quarter’s Performance

Crexus Investment Corp reported its fourth quarter performance on February 19, 2013. The bottom line of $0.23 for the fourth quarter remained in line with expectations, while the book value of $11.85 came down from the linked quarters’ book value of $11.93.

The company reported $20.4 million interest income during the quarter, down 24% from the linked quarter. Much of the decline in the top line of the company was a result of a decline in the weighted average yield on assets during the quarter. The company earned a 10.52% yield on its commercial loans, 11.35% on its preferred equity and 9.55% on its real estate portfolio. This is compared to a 29.86% yield on commercial loans and 7.67% yield on its real estate portfolio during the linked quarter.

Interest expense of $281,000 was up 50% from the linked quarter on higher cost of funds. Cost of funds edged up 1 basis point from the linked quarter to 3.49%. Servicing fees of $152,000 were up 2% over the same time period, providing some support to the net interest income which arrived at $19.97 million, down 25%, compared to the third quarter of 2012.

Other income items during the fourth quarter gave some support to the bottom line. The company realized rental income of $821,000, up 1.5% from the third quarter of the prior year. Other expenses of $5.25 million were up 2% over the same time period. The hike in expense was blamed on the hike in management fees to affiliate, partially offset by a slight decline in the depreciation expense.

As a result, the company posted a net income from continuing operations of $15.53 million. The net income, compared to the linked quarter was down 32%. Net income from discontinued operation of $2.4 million provided further support to the bottom line, which resulted in net income of $17.9 million for the fourth quarter, compared to $22.6 million at the end of the linked quarter of 2012.

Competition

CreXus Investment competes with other mortgage RIETs within the United States. One such mortgage REIT, which happens to be in the process of acquiring CreXus Investment is Annaly Capital Management, Inc. (NYSE:NLY). CreXus announced on Jan. 31, 2013 that it has reached a definitive agreement with Annaly Capital to be acquired for $13 per share in cash. In addition, the share will continue to accrue dividends until the deal closes, which is expected by late April.  Currently CreXus is serving the period under which it is free to solicit, evaluate and enter into negotiations on alternative proposals from third parties through March 16. I believe it’s hard for CreXus to receive another higher bid, given the 9% premium to its book value coupled with the fact that Annaly Capital is the external manager to CreXus, which eliminates any integration risks.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!